
Articles
-
Feb 22, 2024 |
bloomberglinea.com | Dasha Afanasieva |Thomas Mulier
Bloomberg — El director ejecutivo de Nestlé SA, Mark Schneider, dijo que los medicamentos contra la obesidad GLP-1 como Wegovy probablemente aumentarán la demanda de una variedad de productos alimenticios que pueden ayudar a evitar deficiencias de nutrientes.
-
Feb 22, 2024 |
bnnbloomberg.ca | Dasha Afanasieva |Thomas Mulier
(Bloomberg) -- Nestle SA Chief Executive Officer Mark Schneider said GLP-1 obesity drugs like Wegovy will probably increase demand for a range of food products that can help avoid nutrient deficiencies. The company is well-prepared to help users of such treatments with a portfolio that already has annual sales of 1.5 billion Swiss francs ($1.7 billion) including products such as Vital Performance Protein to preserve muscle mass and Garden of Life probiotics to improve gastrointestinal health.
-
Feb 22, 2024 |
bloomberg.com | Dasha Afanasieva |Thomas Mulier
Nestle SA Chief Executive Officer Mark Schneider said GLP-1 obesity drugs like Wegovy will probably increase demand for a range of food products that can help avoid nutrient deficiencies. The company is well-prepared to help users of such treatments with a portfolio that already has annual sales of 1.5 billion Swiss francs ($1.7 billion) including products such as Vital Performance Protein to preserve muscle mass and Garden of Life probiotics to improve gastrointestinal health.
-
Feb 6, 2024 |
nz.news.yahoo.com | Thomas Mulier |John Lauerman
(Bloomberg) -- Novartis AG agreed to buy MorphoSys AG for €2.7 billion ($2.9 billion) as the Swiss pharma company starts following through on plans to use bolt-on acquisitions to beef up its pipeline.
-
Feb 6, 2024 |
ca.finance.yahoo.com | Thomas Mulier |John Lauerman
Thomas Mulier and John LauermanFebruary 6, 2024 at 12:06 a.m.·3 min read(Bloomberg) -- Novartis AG agreed to buy MorphoSys AG for €2.7 billion ($2.9 billion), adding the German drugmaker’s cancer treatments to its pipeline, which the Swiss pharma company has been trying to beef up.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 368
- Tweets
- 1K
- DMs Open
- No